NUC-1031 in biliary tract cancer: from bench to bedside and back? Lenka N. C. BoydGodefridus J. PetersElisa Giovannetti Editorial 31 May 2020 Pages: 1011 - 1014
Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs Wenying Angela LiuLi YuBarbara J. Brennan Review Article 18 May 2020 Pages: 1015 - 1027
Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil Yoshiaki FujimotoRyota NakanishiMasaki Mori Original Article 22 April 2020 Pages: 1029 - 1038
In vivo assessment of the drug interaction between sorafenib and paracetamol in rats Agnieszka KarbownikKatarzyna SobańskaEdyta Szałek Original Article Open access 11 May 2020 Pages: 1039 - 1048
The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats Haitao ChenChao XuQinghua Yao Original Article 15 May 2020 Pages: 1049 - 1062
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer Mansi AroraJames M. BogenbergerMitesh J. Borad Original Article 21 May 2020 Pages: 1063 - 1078
MEK inhibition overcomes everolimus resistance in gastric cancer Hongfang LiuYang YaoJing Li Original Article 22 May 2020 Pages: 1079 - 1087
A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors Tracy Murray StewartApurva A. DesaiRobert A. Casero Jr. Original Article 23 May 2020 Pages: 1089 - 1096
Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway Songbin GuoJinling ZhangZhenfeng Zhang Original Article 24 May 2020 Pages: 1097 - 1108
Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment Ken OgasawaraWilliam B. SmithGopal Krishna Original Article 24 May 2020 Pages: 1109 - 1117
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients Natsumi MatsumotoYutaro KubotaKen-ichi Fujita Original Article 26 May 2020 Pages: 1119 - 1128
Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents Guangan HeXiaolei XieZahid H. Siddik Original Article 28 May 2020 Pages: 1129 - 1140
Exposure–response analysis of endoxifen serum concentrations in early-breast cancer Anabel Beatriz Sanchez-SpitmanDirk-Jan A. R. MoesHenk-Jan Guchelaar Original Article Open access 29 May 2020 Pages: 1141 - 1152
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug Mandy JuarezAlejandro Schcolnik-CabreraAlfonso Duenas-Gonzalez Original Article 30 May 2020 Pages: 1153 - 1163
In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients Jeerawan KlangjorhorAreerak PhanphaisarnDumnoensun Pruksakorn Original Article 31 May 2020 Pages: 1165 - 1176
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model J. H. AzambujaR. S. SchuhE. Braganhol Short Communication 16 May 2020 Pages: 1177 - 1182
Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells Hongjian YangYue LuZhiqiang Ling Expression of Concern 10 April 2020 Pages: 1183 - 1183